Summary. Blood lactate and pyruvate were measured two to three hours after breakfast in 153 patients with maturity-onset (type 2) diabetes. Blood lactate was raised in 56% of all patients taking phenformin and in 35% of all patients taking metformin, while 75% and 35% respectively had raised pyruvate. Mean blood lactate level was raised at 2.2 retool/1 (range 0.2-4.4 mmol/1) in the patients on phenformin and 1.7mmol/1 (range 0.24.3 mmol/1) in those on metformin, with mean blood pyruvate levels of 0.122mmol/1 (range 0.050-0.215mmol/1) and 0.111mmol/1 (range 0.038-0.259 mmol/1) respectively. In patients treated with a sulphonylurea drug alone mean blood lactate and pyruvate levels were not increased and were no different in those receiving sulphonylurea therapy in addition to a biguanide from those receiving a biguanide alone. Blood lactate did not correlate with any clinical or biochemical measurement in any of the treatment groups except for a correlation with serum creatinine in those patients taking mefformin alone. The finding of raised blood lactate levels in diabetic patients treated with metformin suggests that this drug should be prescribed with caution.
Phenformin is known to induce severe lactic acidosis [1] . There is an increasing tendency to substitute metformin as the clinical reports of lactic acidosis due to metformin are rare [2, 3] . Indeed, metformin has been said to have no effect on lactate metabolism [4] . There is a theoretical suggestion that the addition of sulphonylurea therapy and the resulting increase in insulin secretion might reduce the incidence of biguanide-induced lactic acidosis [5] . Also there is a suggestion that small but chronic increases in blood lactate might increase the incidence of diabetic complications [6] .
We have measured blood lactate and pyruvate in patients taking phenformin or metformin alone or in addition to sulphonylurea drugs, as well as in patients taking sulphonylurea drugs alone and in patients on diet alone.
Patients and Methods
A total of 153 patients with maturity-onset diabetes were selected at random from the routine morning Diabetic Clinic. There were six treatment groups. Forty patients were taking metformin either alone [23] or in combination with a sulphonylurea [17]; thirty-six patients were receiving phenformin alone [16] or with a sulphonylurea [20] ; sixty-two patients were receiving a sulphonylurea alone and fifteen patients were on diet only.
Forty-five patients were taking other drugs. These were diuretics (15 patients), analgesics (9 patients), beta-blockers (10 patients), digoxin (4 patients), antidepressants (11 patients), anorectics (2 patients) and glyceryl trinitrate (4 patients).
After informed consent had been obtained a blood sample was taken. All patients had rested for at least 30 min and had last eaten 2-3 h prior to sampling. A free-flowing specimen was obtained after venous occlusion as necessary but without fistclenching. A 1.0 ml aliquot of the sample was then placed immediately in 1.0 ml 10% trichloroacetic acid. Blood lactate and pyruvate were measured by standard en-0012 -186X/78/0014/0095/$1.00 zymatic techniques adapted to a L.K.B. Reaction Rate Analyser [7] . The coefficient of variation for the lactate measurement was 9.4% and for the pyruvate 2.5%. Whole blood glucose was measured by an automated glucose oxidase method. Serum creatinine, urea, electrolytes and liver function tests were measured on a Vickers M300 Multichannel Analyser.
The distribution of the variables measured was not Gaussian, therefore non-parametric statistical techniques (such as the Mann-Whitney 'U' test and the Spearman rank correlation coefficient) were used in the analysis of the results [8] using an Olivetti P642 desk top computer.
Results
The clinical details of the patients are shown in Table 1 . The average age of the patients was similar in each group. The patients on biguanide therapy were heavier on average than other groups whereas the patients taking sulphonylurea plus biguanide therapy had had diabetes for a longer period and had significantly higher blood glucose levels compared to patients on sulphonylurea alone (Table 2) . Biguanide therapy had been prescribed for similar periods in each of the appropriate treatment groups. No patient had clinical or biochemical evidence of renal or hepatic disease.
The mean levels of blood lactate and pyruvate, the lactate/pyruvate ratio, blood glucose and serum creatinine in each group are shown in Table 2 . The mean lactate and pyruvate levels in postprandial blood samples from 13 non-obese normal subjects are included for comparison.
Mean blood lactate levels were significantly raised in patients taking either phenformin or metformin alone or with added suphonylurea therapy. Those patients receiving phenformin alone had a significantly higher mean lactate level than the patients receiving metformin alone but the difference was not significant in those patients also receiving sulphonylurea therapy.
Mean blood pyruvate levels were significantly raised in patients taking phenformin with or without sulphonylureas and in patients taking metformin plus sulphonylureas but not in those taking metformin alone. As with blood lactate levels, there was only a significant difference in mean pyruvate levels between patients taking phenformin or metformin alone but not when the biguanide was taken in combination with a sulphonylurea drug.
Biguanide therapy either with or without added sulphonylurea drugs was also associated with a significant rise in the lactate/pyruvate ratio.
There was no significant difference in lactate or pyruvate levels in diabetic patients on diet alone compared with diabetic patients on sulphonylurea therapy alone or when compared with the normal subjects. Table 3 shows the frequency of raised lactate and pyruvate levels in each treatment group using the 95th percentile level calculated from the normal subjects as the upper limit of normality. Blood lactate was raised in 63% patients on phenformin alone and 22% on metformin alone (a significant difference), 53% on sulphonylurea plus phenformin 95th Percentile for blood lactate in normal subjects -1.85 mmol/l 95th Percentile for blood pyruvate in normal subjects -0.101 mrnol/l significantly higher than diet alone or metformin alone b significantly higher than sulphonylurea & diet and 50% on sulphonylurea plus metformin (not significant). A similar pattern was found with blood pyruvate. In overall terms, 56% patients receiving phenformin had raised blood lactate levels and 35% patients receiving metformin while 75% and 33% patients respectively had raised blood pyruvate levels using these 95th percentile levels as the upper limit of normal.
Blood lactate levels did not correlate with age, body weight, length of clinical diabetes, length of biguanide therapy, blood glucose levels or dose level of biguanide drug (expressed either as mg/day or as mg/kg/day) in any treatment group. There was no significant difference in blood lactate and pyruvate levels comparing male with female patients.
In those patients receiving metformin therapy alone both lactate and pyruvate levels showed a positive correlation with serum creatinine even though the latter was within the normal range. In the group receiving sulphonylurea plus phenformin therapy there was a positive correlation between blood glucose and pyruvate.
In the whole group there was a positive correlation between blood lactate and pyruvate levels.
None of the additional medications made a significant impact on blood lactate or pyruvate. However all four patients taking regular paracetamold-propoxyphene compound tablets ('Distalgesic') had high levels of blood lactate: 3.0 mmol/1 (on glibenclamide); 2.4 mmol/1 (on phenformin); 2.1 mmol/l (on glibenclamide and metformin) and 1.8 mmol/1 (on metformin).
Discussion
These results clearly show that both phenformin and metformin therapy are associated with a high frequency of raised blood lactate in asymptomatic patients attending a routine diabetic clinic. The increase found was much less than that which occurs in the syndrome of lactic acidosis secondary to biguanide therapy (5-35 mmol/l [5, 9] but is similar to that reported in small groups of asymptomatic patients by other workers [10, 11] . The range of values in our patients (0.2-4.4 mmol/l) did not overlap with the range of values reported in severe lactic acidosis. Indeed there is no direct evidence that the patients who develop life-threatening biguanide-induced lactic acidosis come from this group with small, presumably chronic, increase in blood lactate.
In our biguanide-treated patients blood pyruvate levels increased with blood lactate although by a smaller proportion so that the lactate/pyruvate ratio increased. The ratio was raised above normal (< 15) in 64% of our patients on phenformin and in 63% of those on metformin. In the patients on phenformin the ratio ranged from 2 to 39 and from 2 to 32 for those on metformin. These ranges overlap that found in severe lactic acidosis where the ratio varies from 12 to 200 although half are less than 30. It is unlikely therefore that the lactate/ pyruvate ratio could reliably detect or exclude those few biguanide-treated patients likely to develop lactic acidosis.
The low incidence of metformin-induced lactic acidosis is probably due to a true difference in drug effect rather than to a small number of patients being at risk or to misdiagnosis. Nearly all cases of lactic acidosis in patients on metformin have been associated with severe renal failure [3] . There is therefore a general trend towards the prescribing of metformin in place of phenformin. However our results suggest that caution should be applied to the use of metformin particularly in patients with even minor degrees of renal disease or in patients who may undergo a period of anoxia. The need for caution would be further increased if the relationship between increased lactate levels and diabetic complications [6] were to be confirmed.
In our patients the average increase in blood lactate whether associated with phenformin or metformin therapy was the same at all drug doses although other workers have reported such a relationship [12] . Sulphonylurea therapy did not affect blood lactate thus confirming in patients on long-term therapy the findings of Nattrass and colleagues in short-term studies [10, 13] . Sequential studies to show the effect on blood lactate of the addition of sulphonylurea therapy to biguanide-treated patients are not available but our results, by comparison of these groups, suggest that no improvement would occur.
Obesity, a known cause of increased lactate levels [14] , may have contributed to the increased lactate levels found in our patients treated with biguanide drugs alone. However, it is unlikely that obesity was the sole cause of the raised lactate levels associated with biguanide therapy as our patients on sulphonylurea plus biguanide treatment were not significantly more obese.
If our results are confirmed and these small increases in blood lactate are important then the regular measurement of blood lactate in all patients on biguanides is indicated.
